Discover trends, market shifts, and competitive outlooks for the avastin (bevacizumab) global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Avastin (Bevacizumab) Market Size From 2025 to 2034?

The market size for avastin (bevacizumab) has experienced considerable growth in recent years, rising from $7,251.35 million in 2024 to an expected $7,819.19 million in 2025. This demonstrates a compound annual growth rate (CAGR) of 7.8%. Factors such as regulatory sanctions, a rise in the occurrence of cancer, the acceptance of clinicians, the broadening of indication approvals, and reimbursement policies are among the reasons for the growth witnessed in the historic period.

In the upcoming years, the avastin (bevacizumab) market is predicted to experience a significant expansion. It is projected to reach $10,488.97 million by 2029, with a 7.6% compound annual growth rate (CAGR). The potential growth during this predicted period can be ascribed to factors such as enhanced awareness, early diagnosis, the presence of biosimilar competitors, the development of personalized medicine, improved healthcare accessibility, and an augmented focus on precision medicine. Key trends anticipated during this forecast period comprise the rise in combined therapies, a transition towards outpatient services, introduction of patient-focused treatment approaches, acceptance of targeted therapies, and advancements in product innovation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19879&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Avastin (Bevacizumab) Market?

The avastin (bevacizumab) market is expected to grow due to the rise in cancer prevalence. Cancer, described as a collection of diseases caused by the abnormal, unhindered growth and propagation of cells in the body, is becoming increasingly common. Its prevalence is associated with aging populations, lifestyle changes, and more efficient ways of detection. Avastin, used to treat cancer, works by curbing VEGF, thus impeding the development of blood vessels that ferry oxygen and nutrients to cancerous growths, and essentially depriving them of sustenance. The American Cancer Society, a US-based voluntary health entity, predicts roughly 1.9 million fresh cancer diagnoses and around 609,360 cancer-related fatalities to occur in the USA in 2022, which equates to approximately 1,670 deaths daily. Hence, the avastin (bevacizumab) market is poised for growth due to the escalating rate of cancer prevalence. With respect to the avastin (bevacizumab) market, increased healthcare expenditure is set to fuel its expansion. Healthcare expenditure encapsulates the total spending on healthcare goods and services, including individual healthcare, preventive measures, and public health endeavors, all designed to boost health outcomes within a given timeframe. The surge in healthcare expenditure is attributed to factors like an aging demographic, chronic illnesses, cutting-edge medical tech, expensive medications, ineffective payment models, and a higher demand for services. The healthcare expenditure benefits avastin (bevacizumab) by expanding the drug’s accessibility through insurance, thereby fostering market expansion and wider usage among patients. A report by the Office For National Statistics, a UK-based government body, released in May 2024, revealed that total healthcare expenditure witnessed a 5.6% nominal rise between 2022 and 2023, up from a growth rate of 0.9% in 2022. Furthermore, total long-term healthcare and social care spending underwent a 2.8% real-term increase in 2022. Therefore, the avastin (bevacizumab) market is being driven by the growing healthcare expenditure.

Which Key Market Segments Comprise the Avastin (Bevacizumab) Market and Drive Its Revenue Growth?

The avastin (bevacizumab)market covered in this report is segmented –

1) By Dosage: 100 Mg; 400 Mg

2) By Application: Non Squamous Non-Small Cell Lung Cancer; Recurrent Glioblastoma; Cervical Cancer; Colorectal Cell Cancer; Ovarian Cancer; Proliferative Diabetic Retinopathy; Malignant Glioma; Neurofibromatosis; Pancreatic Cancer; Other Applications

3) By Distribution channel: Direct Tender; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

4) By End User: Hospitals; Cancer Supportive Centers; Home Healthcare; Academic And Research Institutes; Other End Users

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19879&type=smp

Which Areas Are Leading Regions in the Avastin (Bevacizumab) Market Expansion Across the Globe?

North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in the avastin (bevacizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Avastin (Bevacizumab) Market Over the Coming Years?

A primary trend within the avastin (bevacizumab) market is steeped in the development of biosimilars as a way to deliver more affordable alternatives and broaden the scope of cancer treatments. Avastin’s biosimilars are essentially biological drugs that shares a close similarity in terms of structure, function, and effectiveness to avastin — a monoclonal antibody predominantly utilized in the treatment of diverse cancers. These biosimilars are revolutionizing cancer management by enhancing access to potent treatments, especially in health care environments that are resource-limited. To illustrate, in October 2022, Amneal Pharmaceuticals Inc., an American pharmaceutical firm, introduced ALYMSYS (bevacizumab-maly), a biosimilar that references Avastin, in the United States. This biosimilar is a vascular endothelial growth factor (VEGF) inhibitor that is used in oncology and is recommended for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and a number of gynecologic cancers.

View the full report here:

https://www.thebusinessresearchcompany.com/report/avastin-bevacizumab-global-market-report

How Is the Avastin (Bevacizumab) Market Conceptually Defined?

Avastin (bevacizumab) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis, the formation of new blood vessels that supply tumors with oxygen and nutrients. It is used in combination with chemotherapy to treat various cancers, including colorectal, lung, kidney, and glioblastoma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19879

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model